In metastatic castration‑resistant prostate cancer, what is the recommended approach for germline and somatic BRCA1/2 testing and eligibility for olaparib therapy?

BRCA1/2 Testing and Olaparib Eligibility in Metastatic Castration-Resistant Prostate Cancer

All patients with metastatic castration-resistant prostate cancer (mCRPC) should undergo both germline and somatic testing for BRCA1/2 mutations (and other HRR genes) as early as possible, ideally at mCRPC diagnosis, to identify candidates for PARP inhibitor therapy. 1, 2

Testing Strategy

When to Test

• Perform testing immediately upon mCRPC diagnosis - do not delay while awaiting treatment decisions 1
• Testing should occur regardless of family history 2
• Both germline AND somatic testing are required, as either can qualify patients for olaparib 1

Testing Methods

• Preferred approach: Metastatic tumor biopsy for histologic and molecular evaluation 1
• Alternative if biopsy unsafe/not feasible: Plasma circulating tumor DNA (ctDNA) assay 1
• Use any commercially available analytically and clinically validated somatic tumor and germline assays 1
• Test for 14 HRR genes: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L 1

Critical Caveat on Germline Testing

If somatic BRCA1/2 mutations are identified, mandatory referral to genetic counseling for germline testing is required - this identifies hereditary cancer predisposition syndromes affecting the patient's personal cancer risk and family members 3, 4

Olaparib Eligibility and Treatment Algorithm

FDA-Approved Indication

Olaparib 300 mg twice daily is approved for mCRPC patients with:

• Deleterious or suspected deleterious germline OR somatic HRR gene mutations in any of 14 genes (listed above)
• Prior treatment with enzalutamide or abiraterone (androgen receptor pathway inhibitor - ARPI)
• Can be used before or after docetaxel 1

NCCN Recommendation Hierarchy

Category 1 (strongest evidence) - BRCA1/2 mutations:

• Preferred option if pre-docetaxel in patients with BRCA1/2 mutations 1
• Strongest survival benefit demonstrated in BRCA2 mutations (HR 0.59 for OS) 1
• BRCA1 mutations show less robust benefit than BRCA2 1

Category 1 - Other HRR genes (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L):

• Approved but heterogeneous response - efficacy driven primarily by BRCA2/BRCA1/ATM cohort 1
• ATM mutations showed minimal OS benefit (HR 0.93) 1
• Very limited data for some genes (e.g., only 4 patients with BRIP1, 2 with RAD51D, 0 with RAD51C in PROfound trial) 1

Do NOT use olaparib:

• PPP2R2A mutations - unfavorable risk/benefit profile 3, 1

Evidence Base

The PROfound trial (phase III) demonstrated:

• Radiographic PFS: HR 0.34 (95% CI 0.25-0.47) in BRCA1/2/ATM cohort 3
• Overall survival: HR 0.69 (95% CI 0.50-0.97) in BRCA1/2/ATM cohort, despite 66% crossover 3
• Cohort B (12 other HRR genes) showed negative primary endpoint with statistical interaction suggesting less benefit 3

Monitoring Requirements During Olaparib Therapy

• Complete blood counts - monitor for anemia requiring transfusion (common) 1
• Hepatic and renal function 1
• Type and screen for potential transfusion support 1
• Dose reductions as needed for severe anemia or intolerance 1

Common Adverse Events

Anemia (including transfusion-requiring), fatigue, nausea/vomiting, anorexia, weight loss, diarrhea, thrombocytopenia, creatinine elevation, cough, dyspnea 1

Rare but Serious Adverse Events

Thromboembolic events (including pulmonary emboli), drug-induced pneumonitis, theoretical risk of myelodysplasia/acute myeloid leukemia 1

Alternative PARP Inhibitor: Rucaparib

Rucaparib is FDA-approved ONLY for BRCA1/2 mutations (not other HRR genes) 1:

• 600 mg twice daily
• Requires prior ARPI treatment
• Category 1, preferred option pre-docetaxel for BRCA1/2 mutations 1
• TRITON3 trial showed median PFS 11.2 vs 6.4 months (HR 0.50) in BRCA1/2 cohort 1
• Do not use in non-BRCA1/2 HRR mutations 1

Key Clinical Pitfalls

1. Testing too late: Many patients receive olaparib in 4th line or later when earlier testing could have optimized sequencing 5, 6
2. Assuming negative germline means no mutation: Somatic-only BRCA mutations occur and qualify for treatment 1
3. Using olaparib for all HRR genes equally: Response is heterogeneous - BRCA2 shows strongest benefit 1, 7
4. Not retesting: Acquired mutations can develop during disease progression 5
5. Forgetting genetic counseling: Somatic BRCA findings require germline confirmation for hereditary syndrome implications 3, 4